Payden & Rygel’s Celgene Corp CELG Stock Holding History

Payden & Rygel’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-176	Closed	-$21K	–	233
2015 Q4	$21K	Buy	+176	New	+$20.4K	﹤0.01%	136

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Payden & Rygel's CELG Position: Q1 2016 in Review

Payden & Rygel sold out of Celgene Corp (CELG) in Q1 2016, closing a stake of 176 shares — an estimated $21K sold.

Payden & Rygel first reported a position in CELG in Q4 2015 and held it in 1 quarter. The position peaked at $21K in Q4 2015. 1,224 funds tracked by Wall St. Rank hold CELG as of Q1 2016.

Payden & Rygel reported no remaining Celgene Corp position as of Q1 2016 after selling out during the quarter.
Payden & Rygel sold 176 Celgene Corp shares in Q1 2016, an estimated $21K.
Payden & Rygel first reported a position in Celgene Corp in Q4 2015 and held it in 1 quarter.
Payden & Rygel's Celgene Corp position peaked at $21K in Q4 2015.
1,224 funds tracked by Wall St. Rank held Celgene Corp as of Q1 2016.

Based on Payden & Rygel's 13F filing for Q1 2016, filed 6 May 2016.